Guoping Xu
Tianjin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Correction: EZH2 blockade reverses doxorubicin resistance by inducing metabolic vulnerability and enhancing DNA damage in breast cancer.
Journal: Frontiers in pharmacology
Published: May 15, 2026
EZH2 blockade reverses doxorubicin resistance by inducing metabolic vulnerability and enhancing DNA damage in breast cancer.
Journal: Frontiers in pharmacology
Published: January 13, 2026
Engineering MnPt Bimetallic Nanozymes for Cascade Enzymatic Therapy and Enhanced Radio-Immunotherapy.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: September 30, 2025
SAM2-Aug: Prior knowledge-based Augmentation for Target Volume Auto-Segmentation in Adaptive Radiation Therapy Using Segment Anything Model 2.
Journal: ArXiv
Published: July 31, 2025
Primary adrenal melanoma with extensive metastasis: a case report and literature review.
Journal: Frontiers in oncology
Published: June 26, 2025
Mitophagy related gene signature for prognosis and therapeutic evaluation in KIRC.
Journal: Scientific reports
Published: December 27, 2024
Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High-Risk Non-Muscle-Invasive Bladder Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 06, 2024
Phase 2 Study of Preoperative Tislelizumab in Combination with Low-dose Nab-Paclitaxel in Patients with Muscle-invasive Bladder Cancer.
Journal: European urology oncology
Published: January 07, 2024
Preclinical Evaluation of a Protein-Based Nanoscale Contrast Agent for MR Angiography at an Ultralow Dose.
Journal: International journal of nanomedicine
Published: May 03, 2023
The emerging landscape of long non-coding RNAs in hepatocellular carcinoma.
Journal: International journal of clinical and experimental pathology
Published: May 06, 2021
Knockdown of long noncoding RNA colorectal neoplasia differentially expressed inhibits hepatocellular carcinoma progression by mediating the expression of nuclear autoantigenic sperm protein.
Journal: Oncology reports
Published: April 16, 2021
Last Updated: 09/26/2026